Skip to main content
EJNMMI Research
Fig. 5 | EJNMMI Research

Fig. 5

From: Early 18F-FDG uptake as a reliable imaging biomarker of T790M-mediated resistance but not MET amplification in non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors

Fig. 5

Tumor levels of glycolytic enzymes and OXPHOS in H1975 and H1993 xenografts. Surgically removed H1975 and H1993 tumors were homogenized and tested for levels of key glycolytic proteins (a) and subunits of mitochondrial complexes (b) by western blot analysis in response to each treatment. The bands were quantified by morphodensitometric analysis using ImageJ software. Data are expressed as relative protein levels of each treated sample compared to the corresponding vehicle-treated internal control. Significant differences versus vehicle-treated animals were indicated with *p < 0.05, **p < 0.01; significant differences versus erlotinib-treated animals were indicated with # p < 0.05 and ## p < 0.01

Back to article page